AMCP Market Insights Findings Show Uncertainty in Biomarker Testing for ESR1-Mutated Advanced Breast Cancer as Payers Weigh Earlier Detection and a Growing Class of Targeted Therapies

Summary

AMCP Market Insights findings highlight payer uncertainty around biomarker testing for ESR1-mutated, HR+/HER2- advanced breast cancer and the growing class of targeted therapies. The article is a market-insights/policy piece with no specific company, drug, or trial event reported in the excerpt.